immunosuppressant_mabs
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| immunosuppressant_mabs [2023/08/22 05:00] – [anti-IgE monoclonal antibodies] gary1 | immunosuppressant_mabs [2026/08/13 07:49] (current) – [anti-TNF-α monoclonal antibodies] wh | ||
|---|---|---|---|
| Line 36: | Line 36: | ||
| * binds and neutralizes TNF-α and induces apoptosis in active T-cells | * binds and neutralizes TNF-α and induces apoptosis in active T-cells | ||
| * initially approved for use in treating Crohn disease, infliximab has since been approved for use in ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, | * initially approved for use in treating Crohn disease, infliximab has since been approved for use in ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, | ||
| - | * Adalimumab/ | + | * Adalimumab |
| * Certolizumab pegol - may have higher risk of serious infections than others in this group | * Certolizumab pegol - may have higher risk of serious infections than others in this group | ||
| * Golimumab | * Golimumab | ||
immunosuppressant_mabs.txt · Last modified: 2026/08/13 07:49 by wh